Загрузка...
Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer
Histone deacetylase (HDAC) is overexpressed in multiple cancers including pancreatic cancer (PC). However, the effects of histone deacetylase inhibitor (HDACi) on apoptosis and epithelial-mesenchymal transition (EMT) differ in various cancers. In this study, we aimed to investigate the anti-tumor ef...
Сохранить в:
| Опубликовано в: : | Am J Cancer Res |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
e-Century Publishing Corporation
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6325471/ https://ncbi.nlm.nih.gov/pubmed/30662800 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|